A Phase II Study to Evaluate the Efficacy of ThromboView® in the Detection of Pulmonary Emboli

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to determine the diagnostic accuracy of 99mTc ThromboView® SPECT imaging for the detection of acute pulmonary embolism (PE) in patients for whom there is a moderate to high clinical suspicion for PE.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events

NCT03183063

Pulmonary Thromboembolisms Pulmonary Embolism

COMPLETED NA

Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus Anticoagulation Alone

NCT05133713

Pulmonary Embolism Pulmonary Hypertension Chronic Thromboembolic Pulmonary Hypertension

UNKNOWN

Aventus Thrombectomy System Pulmonary Embolism Clinical Study

NCT05907564

Pulmonary Embolism Embolism Embolism and Thrombosis +4 more

COMPLETED NA

Pulmonary Perfusion by Iodine Subtraction Mapping CT Angiography in Acute Pulmonary Embolism

NCT03579849

Pulmonary Embolism

COMPLETED NA

Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED II)

NCT00007085

Lung Diseases Pulmonary Embolism Venous Thromboembolism

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Pulmonary Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ThromboView

Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written consent by the subject to participate in the study.
2. Moderate to high pre-test probability of acute pulmonary embolism.
3. Positive D-dimer.
4. Onset of PE symptoms occurring within the last seven days.
5. Aged 18 years or older.
6. Women of childbearing potential must have a negative serum pregnancy test (β-hCG) result at the time of enrollment into the study. Both male and female participants must agree to use effective contraception for the first 30 days after administration of 99mTc ThromboView®.

Exclusion Criteria

1. The subject is unwilling or unable to provide written informed consent.
2. Allergy or other contraindication to intravenous iodinated contrast media.
3. Prior exposure to murine, chimeric or humanized antibodies.
4. Illicit intravenous drug use in the past 12 months.
5. Administration of therapeutic radioiodine in the past 6 months.
6. Life expectancy less than 90 days.
7. Previous participation in the current study.
8. Current enrollment in a clinical trial involving any other investigational agent.
9. Subject is unsuitable for SPECT scanning at the study Investigator's discretion (e.g. residual detectable radioactivity within the lungs due to prior imaging studies or treatment, preceding planned administration of 99mTc ThromboView®).
10. Inability to perform CTPA or 99mTc ThromboView imaging, for any reason.
11. Renal dysfunction: calculated creatinine clearance \< 30 mL/min.
12. Hepatic dysfunction: serum transaminases ≥ 3 x upper limit of normal range.
13. Hepatic dysfunction: subject has history of chronic or currently active liver disease.
14. Current pregnancy or lactation or conception intended within three months of enrollment.
15. Subject is unsuitable for the study at the study Investigator's discretion. -

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No